Oxaspiro Pyrrolopyrazole MOR Agonists With Reduced β-Arrestin Bias
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid drugs, such as morphine, exhibit long-term tolerance and side effects like respiratory depression and constipation due to their activation of the β-arrestin pathway, which can be mitigated by designing negatively β-arrestin-biased ligands for the MOR receptor.
Innovation Solution
Development of optically pure oxaspiro-substituted pyrrolopyrazole derivatives that act as MOR receptor agonists, primarily activating the G-protein signaling pathway while minimizing β-arrestin-mediated desensitization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional opioid drugs (e.g., morphine) are used to activate MOR receptors for analgesic effects, then pain relief is achieved, but β-arrestin pathway activation causes tolerance and side effects (respiratory depression, constipation)
Solution Approach 1:
The patent applies local quality by designing ligands with specific molecular structures (oxaspiro-substituted pyrrolopyrazole derivatives with particular substituent patterns at R1-R6 positions) that selectively engage the G-protein pathway while avoiding β-arrestin recruitment. This structural differentiation creates localized interaction properties at the receptor binding site that favor G-protein coupling over β-arrestin binding, thereby achieving analgesia without the harmful side effects associated with β-arrestin activation
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the ligand structure (substituent types, positions, and configurations on the pyrrolopyrazole core and oxaspiro moiety) to modulate the balance between G-protein and β-arrestin pathway activation. By adjusting these chemical parameters, the ligands achieve optimized signaling bias toward G-proteins, maintaining analgesic efficacy while minimizing β-arrestin-mediated tolerance and side effects
2Duration of action of moving object
If ligands are designed to be negatively β-arrestin-biased to reduce side effects, then β-arrestin-mediated desensitization is minimized, but achieving sufficient G-protein signaling potency requires precise molecular optimization
Solution Approach 1:
The patent applies segmentation by dividing the ligand molecule into distinct functional segments: a pyrrolopyrazole core structure (providing baseline MOR affinity), an oxaspiro substituent group (modulating signaling bias), and variable R1-R6 substituents (fine-tuning G-protein vs. β-arrestin selectivity). This modular segmentation allows independent optimization of each segment's contribution to overall activity, enabling precise control over signaling pathway bias while managing molecular complexity through systematic structure-activity relationship exploration
Data Source
AI summary
Disclosed are an optically pure oxaspiro-substituted pyrrolopyrazole derivative, a preparation method therefor and the pharmaceutical use thereof. The compounds are compounds as shown in formula (I) and formula (II) or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug thereof. Also disclosed are a preparation method therefor and the use thereof.